Korean J Radiol.  2018 Aug;19(4):545-559. 10.3348/kjr.2018.19.4.545.

Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources

• Lee DH
• Lee JM

• KMID: 2413684
• DOI: http://doi.org/10.3348/kjr.2018.19.4.545

Abstract

Radiofrequency ablation (RFA) has emerged as an effective loco-regional treatment modality for malignant hepatic tumors. Indeed, studies have demonstrated that RFA of early stage hepatocellular carcinomas can provide comparable overall survival to surgical resection. However, the incidence of local tumor progression (LTP) after RFA is significantly higher than that of surgical resection. Thus, to overcome this limitation, multiple electrode radiofrequency (RF) systems that use a multi-channel RF generator have been developed, and they demonstrate better efficiency in creating larger ablation zones than that using the conventional RFA with a single electrode. Furthermore, RFA with multiple electrodes can allow the "no-touch" ablation technique which may also help to reduce LTP. Another technique that would be helpful in this regard is multi-modality-ultrasound fusion imaging, which helps to not only more accurately determine the target lesion by enabling the RFA of small, poorly visible or invisible tumors, but also improve the monitoring of procedures and determine the appropriateness of the ablation margin. In addition, new energy sources, including microwave and cryoablation, have been introduced in imaging-guided tumor ablation. In this review, these recently introduced ablation techniques and the results of the most current animal and clinical studies are discussed.

Keyword

Radiofrequency ablation; Malignant hepatic tumors; Liver; Multiple electrodes; Fusion imaging technique; Hepatocellular carcinomas (HCCs); Microwave; Cryoablation

MeSH Terms

Ablation Techniques
Animals
Carcinoma, Hepatocellular
Catheter Ablation*
Cryosurgery
Electrodes*
Incidence
Liver*
Microwaves

Figure

• 

  Fig. 1 Diagram showing use of three electrodes with various RF energy delivery methods. A. Single switching monopolar mode: RF energy is delivered to one of three electrodes at given time, and switched to adjacent electrode. Ground pad serves as passive electrode. B. Dual switching monopolar mode: RF energy is simultaneously delivered to pair of electrodes among three inserted electrodes at given time, and switched to pair of electrodes. Ground pad serves as passive electrode. C. Switching bipolar mode: pair of electrodes is activated, and then switched to another pair of electrodes: one electrode serves as active electrode and other as passive electrode. Green circle: inserted electrode; red circle: active electrode; blue circle and blue bar: passive electrode; and light orange or eclipse: ablation zone. RF = radiofrequency

• 

  Fig. 2 Switching monopolar RFA with multiple electrodes for medium-sized HCCs. A. Contrast-enhanced arterial phase transverse CT image displays 4.2 cm enhancing mass in segment VII of liver. B. Portal venous phase transverse CT image shows wash-out of tumor, which indicated HCC. C, D. Under US guidance, three electrodes with 3-cm active tip (arrows) are placed across index tumor. E. After RF energy delivery with switching monopolar mode, echo-cloud of microbubbles are generated, encompassing index tumor. F. One-month follow-up contrast-enhanced portal venous phase transverse CT image displays complete ablation of index tumor without evidence of viable residual tumor. CT = computed tomography, HCCs = hepatocellular carcinomas, RFA = radiofrequency ablation, US = ultrasound

• 

  Fig. 3 RFA for HCC using multiple electrodes with “no-touch” technique under fusion imaging guidance. A. Contrast-enhanced arterial phase transverse CT image displays 1.5-cm enhancing nodular lesion (arrow) in segment VI of liver, which suggests HCC. B. Fusion imaging technique between real-time working US and reference arterial phase CT images clearly display low echoic target lesion on US image. C. Under fusion imaging guidance, two electrodes (arrows) are inserted outside of target tumor (*). Tumor itself is not violated during electrode insertion. D. After RF energy delivery, echo-cloud of micro-bubbles is created around target tumor. E. Echo-cloud of microbubbles completely covers target tumor, which suggests successful ablation of target tumor. F. Immediate follow-up contrast-enhanced portal venous phase transverse CT image demonstrates complete destruction of target tumor with sufficient ablation margin.

• 

  Fig. 4 Process of fusion imaging between real-time US and reference MR images. A. Plane registration: after loading of reference MR images to US equipment that implemented fusion imaging technique; plane registration was done. In this case, sagittal plane was used for plane registration. B. Point registration: after plane registration, point registration was performed by selecting same anatomic landmark (proximal right portal vein in this case) on both real-time working US and reference MR images. C. Target tumor marking: after point registration, targeted tumor was marked on reference MR image. Location of targeted tumor on real-time working US was immediately visualized in corresponding location. MR = magnetic resonance

• 

  Fig. 5 RFA of small invisible tumor on conventional B-mode US under fusion imaging guidance. A. Subtraction image from arterial phase gadoxetic acid-enhanced MR image to precontrast MR image demonstrates 1.2-cm arterial enhancing nodular lesion in segment V subcapsular portion of liver (arrow). There is non-enhancing area (*) due to previous ablation therapy. B. Hepatobiliary phase image displays low signal intensity within tumor (arrow), which suggests HCC. Previous ablation zone also exhibited low signal intensity (*). C. On conventional B-mode US image, there is no focal lesion corresponding to HCC that is visible on gadoxetic acid-enhanced MR. D. Under fusion imaging guidance between real-time working US and reference hepatobiliary phase MR images, location of index tumor is determined, and electrode is inserted. E. After RF energy delivery, echo-cloud of micro-bubbles is created and encompasses index tumor. F. Immediate follow-up contrast-enhanced portal venous phase transverse CT image displays complete destruction of target tumor with sufficient ablation margin.

Reference

1. Ahmed M. Technology Assessment Committee of the Society of Interventional Radiology. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update: supplement to the consensus document. J Vasc Interv Radiol. 2014; 25:1706–1708.

2. Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int. 2012; 32:1434–1442.

3. Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009; 9:31.

4. Lencioni R, de Baere T, Martin RC, Nutting CW, Narayanan G. Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies - a western perspective. Liver Cancer. 2015; 4:208–214.

5. Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional therapy of hepatocellular carcinoma. Clin Liver Dis. 2015; 19:401–420.

6. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001; 221:159–166.

7. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology. 2009; 50:1475–1483.

8. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107:569–577. quiz 578.

9. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013; 58:89–97.

10. Minami Y, Kudo M. Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. Gut Liver. 2013; 7:1–6.

11. Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, Kim YJ, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014; 270:900–909.

12. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006; 243:321–328.

13. Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59:300–307.

14. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245–1255.

15. Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes--a 10-year experience at a single center. Radiology. 2016; 278:601–611.

16. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010; 195:758–765.

17. Kang TW, Lee MW, Song KD, Rhim H, Lim HK, Kang W, et al. Ultrasound-guided radiofrequency ablation using a new electrode with an electromagnetic position sensor for hepatic tumors difficult to place an electrode: a preliminary clinical study. Cardiovasc Intervent Radiol. 2017; 40:1891–1898.

18. Ahn SJ, Lee JM, Lee DH, Lee SM, Yoon JH, Kim YJ, et al. Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017; 66:347–354.

19. Lee MW, Rhim H, Cha DI, Kim YJ, Choi D, Kim YS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol. 2012; 198:1438–1444.

20. Lee MW, Rhim H, Cha DI, Kim YJ, Lim HK. Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1–3 cm): value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol. 2013; 24:958–965.

21. Lee MW. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography. 2014; 33:227–239.

22. Kang TW, Rhim H. Recent advances in tumor ablation for hepatocellular carcinoma. Liver Cancer. 2015; 4:176–187.

23. Brace CL, Sampson LA, Hinshaw JL, Sandhu N, Lee FT Jr. Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model. J Vasc Interv Radiol. 2009; 20:118–124.

24. Chang W, Lee JM, Yoon JH, Lee DH, Lee SM, Lee KB, et al. No-touch radiofrequency ablation using multiple electrodes: an in vivo comparison study of switching monopolar versus switching bipolar modes in porcine livers. PLoS One. 2017; 12:e0176350.

25. Lee J, Lee JM, Yoon JH, Lee JY, Kim SH, Lee JE, et al. Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas. Korean J Radiol. 2012; 13:34–43.

26. Mulier S, Miao Y, Mulier P, Dupas B, Pereira P, de Baere T, et al. Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. Eur Radiol. 2005; 15:798–808.

27. Denys AL, De Baere T, Kuoch V, Dupas B, Chevallier P, Madoff DC, et al. Radio-frequency tissue ablation of the liver: in vivo and ex vivo experiments with four different systems. Eur Radiol. 2003; 13:2346–2352.

28. Pereira PL, Trübenbach J, Schenk M, Subke J, Kroeber S, Schaefer I, et al. Radiofrequency ablation: in vivo comparison of four commercially available devices in pig livers. Radiology. 2004; 232:482–490.

29. Ni Y, Mulier S, Miao Y, Michel L, Marchal G. A review of the general aspects of radiofrequency ablation. Abdom Imaging. 2005; 30:381–400.

30. Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. J Vasc Interv Radiol. 2001; 12:1021–1032.

31. Goldberg SN. Radiofrequency tumor ablation: principles and techniques. Eur J Ultrasound. 2001; 13:129–147.

32. Lee JM, Han JK, Kim SH, Lee JY, Kim DJ, Lee MW, et al. Saline-enhanced hepatic radiofrequency ablation using a perfused-cooled electrode: comparison of dual probe bipolar mode with monopolar and single probe bipolar modes. Korean J Radiol. 2004; 5:121–127.

33. Dodd GD 3rd, Frank MS, Aribandi M, Chopra S, Chintapalli KN. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. AJR Am J Roentgenol. 2001; 177:777–782.

34. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities--part II. J Vasc Interv Radiol. 2001; 12:1135–1148.

35. Chen MH, Yang W, Yan K, Zou MW, Solbiati L, Liu JB, et al. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients--mathematic model, overlapping mode, and electrode placement process. Radiology. 2004; 232:260–271.

36. Lee JM, Han JK, Kim HC, Choi YH, Kim SH, Choi JY, et al. Switching monopolar radiofrequency ablation technique using multiple, internally cooled electrodes and a multichannel generator: ex vivo and in vivo pilot study. Invest Radiol. 2007; 42:163–171.

37. Laeseke PF, Frey TM, Brace CL, Sampson LA, Winter TC 3rd, Ketzler JR, et al. Multiple-electrode radiofrequency ablation of hepatic malignancies: initial clinical experience. AJR Am J Roentgenol. 2007; 188:1485–1494.

38. Woo S, Lee JM, Yoon JH, Joo I, Kim SH, Lee JY, et al. Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results. Radiology. 2013; 268:589–600.

39. Choi JW, Lee JM, Lee DH, Yoon JH, Suh KS, Yoon JH, et al. Switching monopolar radiofrequency ablation using a separable cluster electrode in patients with hepatocellular carcinoma: a prospective study. PLoS One. 2016; 11:e0161980.

40. Yoon JH, Lee JM, Han JK, Choi BI. Dual switching monopolar radiofrequency ablation using a separable clustered electrode: comparison with consecutive and switching monopolar modes in ex vivo bovine livers. Korean J Radiol. 2013; 14:403–411.

41. Yoon JH, Lee JM, Hwang EJ, Hwang IP, Baek J, Han JK, et al. Monopolar radiofrequency ablation using a dual-switching system and a separable clustered electrode: evaluation of the in vivo efficiency. Korean J Radiol. 2014; 15:235–244.

42. Choi TW, Lee JM, Lee DH, Lee JH, Yu SJ, Kim YJ, et al. Percutaneous dual-switching monopolar radiofrequency ablation using a separable clustered electrode: a preliminary study. Korean J Radiol. 2017; 18:799–808.

43. Lee JM, Han JK, Kim SH, Lee JY, Shin KS, Choi BI. An ex-vivo experimental study on optimization of bipolar radiofrequency liver ablation using perfusion-cooled electrodes. Acta Radiol. 2005; 46:443–451.

44. Hocquelet A, Aubé C, Rode A, Cartier V, Sutter O, Manichon AF, et al. Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. J Hepatol. 2017; 66:67–74.

45. Seror O, Sutter O. RE: should we use a monopolar or bipolar mode for performing no-touch radiofrequency ablation of liver tumors? Clinical practice might have already resolved the matter once and for all. Korean J Radiol. 2017; 18:749–752.

46. Yoon JH, Lee JM, Woo S, Hwang EJ, Hwang I, Choi W, et al. Switching bipolar hepatic radiofrequency ablation using internally cooled wet electrodes: comparison with consecutive monopolar and switching monopolar modes. Br J Radiol. 2015; 88:20140468.

47. Espinoza S, Briggs P, Duret JS, Lapeyre M, de Baère T. Radiofrequency ablation of needle tract seeding in hepatocellular carcinoma. J Vasc Interv Radiol. 2005; 16:743–746.

48. Jaskolka JD, Asch MR, Kachura JR, Ho CS, Ossip M, Wong F, et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol. 2005; 16:485–491.

49. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007; 33:437–444.

50. Llovet JM, Vilana R, Brü C, Bianchi L, Salmeron JM, Boix L, et al. Barcelona Clínic Liver Cancer (BCLC) Group. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001; 33:1124–1129.

51. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002; 89:1206–1222.

52. Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: local control rate and risk of peritoneal seeding at long-term follow-up. Clin Radiol. 2013; 68:e641–e651.

53. Seror O, N’Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, et al. Hepatocellular carcinoma within Milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results. Radiology. 2016; 280:611–621.

54. Lee DH, Lee JM, Yoon JH, Kim YJ, Han JK. Thermal injury-induced hepatic parenchymal hypoperfusion: risk of hepatocellular carcinoma recurrence after radiofrequency ablation. Radiology. 2017; 282:880–891.

55. Chang W, Lee JM, Lee SM, Han JK. No-touch radiofrequency ablation: a comparison of switching bipolar and switching monopolar ablation in ex vivo bovine liver. Korean J Radiol. 2017; 18:279–288.

56. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol. 2016; 17:93–102.

57. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013; 19:3872–3882.

58. Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2013; 25:187–194.

59. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005; 234:961–967.

60. Rhim H, Lee MH, Kim YS, Choi D, Lee WJ, Lim HK. Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas. AJR Am J Roentgenol. 2008; 190:1324–1330.

61. Lee MW, Lim HK, Kim YJ, Choi D, Kim YS, Lee WJ, et al. Percutaneous sonographically guided radio frequency ablation of hepatocellular carcinoma: causes of mistargeting and factors affecting the feasibility of a second ablation session. J Ultrasound Med. 2011; 30:607–615.

62. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208–1236.

63. European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908–943.

64. Lee DH, Lee JM, Lee JY, Kim SH, Kim JH, Yoon JH, et al. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation. J Hepatol. 2015; 62:1122–1130.

65. Maybody M, Stevenson C, Solomon SB. Overview of navigation systems in image-guided interventions. Tech Vasc Interv Radiol. 2013; 16:136–143.

66. Ewertsen C, Sáftoiu A, Gruionu LG, Karstrup S, Nielsen MB. Real-time image fusion involving diagnostic ultrasound. AJR Am J Roentgenol. 2013; 200:W249–W255.

67. Abi-Jaoudeh N, Kruecker J, Kadoury S, Kobeiter H, Venkatesan AM, Levy E, et al. Multimodality image fusion-guided procedures: technique, accuracy, and applications. Cardiovasc Intervent Radiol. 2012; 35:986–998.

68. Song KD, Lee MW, Rhim H, Cha DI, Chong Y, Lim HK. Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol. 2013; 201:1141–1147.

69. Crocetti L, Lencioni R, Debeni S, See TC, Pina CD, Bartolozzi C. Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system. Invest Radiol. 2008; 43:33–39.

70. Lee JY, Choi BI, Chung YE, Kim MW, Kim SH, Han JK. Clinical value of CT/MR-US fusion imaging for radiofrequency ablation of hepatic nodules. Eur J Radiol. 2012; 81:2281–2289.

71. Lee MW, Kim YJ, Park HS, Yu NC, Jung SI, Ko SY, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol. 2010; 194:W396–W400.

72. Minami T, Minami Y, Chishina H, Arizumi T, Takita M, Kitai S, et al. Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging. Oncology. 2014; 87:Suppl 1. 55–62.

73. Lim S, Lee MW, Rhim H, Cha DI, Kang TW, Min JH, et al. Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas. J Vasc Interv Radiol. 2014; 25:307–314.

74. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014; 273:241–260.

75. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010; 17:171–178.

76. Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. 2013; 82:1379–1384.

77. Lee KF, Hui JW, Cheung YS, Wong JS, Chong CN, Wong J, et al. Surgical ablation of hepatocellular carcinoma with 2.45-GHz microwave: a critical appraisal of treatment outcomes. Hong Kong Med J. 2012; 18:85–91.

78. Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc. 2014; 28:3429–3434.

79. Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015; 7:1054–1063.

80. Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005; 40:1054–1060.

81. Song KD. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol. 2016; 22:509–515.

82. Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015; 61:1579–1590.